WHO recommendations: uterotonics for the prevention of postpartum haemorrhage
2018 update
20 December 2018
| Guideline

Overview
The primary audience for these recommendations includes health professionals who are responsible for developing national and local health care guidelines and protocols (particularly those related to postpartum haemorrhage (PPH) prevention and treatment) and those involved in the provision of care to women and their newborns during labour and childbirth, including midwives, nurses, general medical practitioners and obstetricians, as well as managers of maternal and child health programmes, and relevant staff in ministries of health and training institutions, in all settings.
Web annexes (GRADE Evidence to Decision frameworks and Summary of Findings tables)
- Oxytocin versus placebo or no treatment
- Carbetocin versus placebo or no treatment
- Misoprostol versus placebo or no treatment
- Ergometrine/methylergometrine versus placebo or no treatment
- Oxytocin and ergometrine versus placebo or no treatment
- Injectable prostaglandins versus placebo or no treatment
- Choice of uterotonic agents
WHO Team
Guidelines Review Committee,
Sexual and Reproductive Health and Research (SRH)
Editors
WHO
Number of pages
43
Reference numbers
ISBN: 978-92-4-155042-0